Modifications of The Human Liver Cancer Cells through microRNA-145-Mediated Targeting of CDCA3

Document Type : Original Article

Authors

The Second Department of General Surgery, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China

Abstract

Objective: Owing to the lethality of liver cancer, it is considered as one of the devastating types of cancers across the globe. Consistently, the study was designed to elucidate the role and to explore the therapeutic implications of miR-145 in human liver cancer. Materials & methods: In the current experimental study, gene expression was determined by RT-PCR analysis. Transfection of cancer cells was carried out using Lipofectamine 2000. The cell proliferation of liver cancer cells was estimated by MTT assay. Clonogenic assay was performed for analysis of colony forming potential of cancer cells. Flow cytometry was done to analyze the cell cycle phase distribution of cancer cells. Transwell chamber assay was performed to assess the motility of cancer cells. Western blotting was done to estimate the expression levels of proteins. Dual luciferase assay was performed for interaction analysis of miR-145 with CDCA3. Result: The miR-145 expression was found to be downregulated in liver cancer cells. The transfection mediated overexpression of miR-145 inhibited the cancer cell proliferation and when miR-145 inhibitor was transfected, cancer cells showed higher proliferation rates. Enrichment of miR-145 levels led to cell cycle arrest at G2/M phase by inhibiting cyclin B1. miR-145 also restricted the migration and invasion of cancer cells. CDCA3 was shown to be the intracellular target of miR-145 and it was found that the inhibitory effects of miR-145 were modulated through CDCA3, intracellularly. Conclusion: The current study clearly revealed that there is a need to investigate the regulatory role of different molecular entities like microRNAs in cancer development to better understand mechanics behind this pathogenesis and design more effective combating strategies against cancer.

Keywords

Main Subjects

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.
  2. Zheng R, Qu C, Zhang S, Zeng H, Sun K, Gu X, et al. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chin J Cancer Res. 2018; 30(6): 571-579.
  3. Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer. 2016; 139(7): 1534- 1545.
  4. Zhang Y, Ren JS, Shi JF, Li N, Wang YT, Qu C, et al. International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer. 2015; 15: 94.
  5. Maemura K, Natsugoe S, Takao S. Molecular mechanism of cholangiocarcinoma carcinogenesis. J Hepatobiliary Pancreat Sci. 2014; 21(10): 754-760.
  6. Valashedi MR, Bamshad C, Najafi-Ghalehlou N, Nikoo A, Tomita K, Kuwahara Y, et al. Non-coding RNAs in ferroptotic cancer cell death pathway: meet the new masters. Hum Cell. 2022; 35(4): 972- 994.
  7. Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019; 234(5): 5451-5465.
  8. Xu X, Tao Y, Shan L, Chen R, Jiang H, Qian Z, et al. The role of MicroRNAs in hepatocellular carcinoma. J Cancer. 2018; 9(19): 3557-3569.
  9. Qian W, Zhang Z, Peng W, Li J, Gu Q, Ji D, et al. CDCA3 mediates p21-dependent proliferation by regulating E2F1 expression in colorectal cancer. Int J Oncol. 2018; 53(5): 2021-2033.
  10. Chen Q, Zhou L, Ye X, Tao M, Wu J. miR-145-5p suppresses proliferation, metastasis and EMT of colorectal cancer by targeting CDCA3. Pathol Res Pract. 2020; 216(4): 152872.
  11. O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018; 9: 402.
  12. Sud N, Taher J, Su Q. MicroRNAs and noncoding RNAs in hepatic lipid and lipoprotein metabolism: potential therapeutic targets of metabolic disorders. Drug Dev Res. 2015; 76(6): 318-327.
  13. Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech. 2021; 14(4): dmm047662.
  14. Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016; 1: 15004.
  15. Fang T, Lv H, Lv G, Li T, Wang C, Han Q, et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun. 2018; 9(1): 191.
  16. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122--a key factor and therapeutic target in liver disease. J Hepatol. 2015; 62(2): 448-457.
  17. Eades G, Wolfson B, Zhang Y, Li Q, Yao Y, Zhou Q. lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res. 2015; 13(2): 330-338.
  18. Wang RJ, Zheng YH, Wang P, Zhang JZ. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 2015; 8(1): 765-771.
  19. Ding W, Tan H, Zhao C, Li X, Li Z, Jiang C, et al. MiR-145 suppresses cell proliferation and motility by inhibiting ROCK1 in hepatocellular carcinoma. Tumour Biol. 2016; 37(5): 6255-6260.
  20. Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang Z, et al. MiR-145, miR- 133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett. 2014; 588(7): 1168-1177.
  21. Hajibabaei S, Sotoodehnejadnematalahi F, Nafissi N, Zeinali S, Azizi M. Aberrant promoter hypermethylation of miR-335 and miR- 145 is involved in breast cancer PD-L1 overexpression. Sci Rep. 2023; 13(1): 1003.
  22. Zhang Y, Cheng Y, Zhang Z, Bai Z, Jin H, Guo X, et al. CDCA2 Inhibits apoptosis and promotes cell proliferation in prostate cancer and is directly regulated by HIF-1α pathway. Front Oncol. 2020; 10: 725.

Files

Share

How to cite

Statistics